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Abstract Apixaban (BMS-562247; 1-(4-methoxyphenyl)-
7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-
1H-pyrazolo[3,4-c]pyridine-3-carboxamide), a direct
inhibitor of activated factor X (FXa), is in development for
the prevention and treatment of various thromboembolic
diseases. With an inhibitory constant of 0.08 nM for human
FXa, apixaban has greater than 30,000-fold selectivity for
FXa over other human coagulation proteases. It produces a
rapid onset of inhibition of FXa with association rate
constant of 20 lM
-1/s approximately and inhibits free as
well as prothrombinase- and clot-bound FXa activity in
vitro. Apixaban also inhibits FXa from rabbits, rats and
dogs, an activity which parallels its antithrombotic potency
in these species. Although apixaban has no direct effects on
platelet aggregation, it indirectly inhibits this process by
reducing thrombin generation. Pre-clinical studies of
apixaban in animal models have demonstrated dose-
dependent antithrombotic efﬁcacy at doses that preserved
hemostasis. Apixaban improves pre-clinical antithrombotic
activity, without excessive increases in bleeding times,
when added on top of aspirin or aspirin plus clopidogrel at
their clinically relevant doses. Apixaban has good
bioavailability, low clearance and a small volume of dis-
tribution in animals and humans, and a low potential for
drug–drug interactions. Elimination pathways for apixaban
include renal excretion, metabolism and biliary/intestinal
excretion. Although a sulfate conjugate of O-demethyl
apixaban (O-demethyl apixaban sulfate) has been identiﬁed
as the major circulating metabolite of apixaban in humans,
it is inactive against human FXa. Together, these non-
clinical ﬁndings have established the favorable pharmaco-
logical proﬁle of apixaban, and support the potential use of
apixaban in the clinic for the prevention and treatment of
various thromboembolic diseases.
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Introduction
Thrombosis is a major cause of morbidity and mortality in
the Western world and plays a pivotal role in the patho-
genesis of numerous cardiovascular disorders, including
acute coronary syndrome (ACS) (i.e. unstable angina and
myocardial infarction), sudden cardiac death, peripheral
arterial occlusion, ischemic stroke, deep vein thrombosis
(DVT) and pulmonary embolism. Despite recent advances
in interventional and drug therapy for thrombosis, the
burden of thrombotic disease remains unacceptably high
[1, 2]. There is therefore a signiﬁcant need for new anti-
thrombotic therapies that are more effective and provide
improved safety proﬁle compared with current treatments.
This review focuses on the pre-clinical discovery of apix-
aban, a promising new oral antithrombotic agent that spe-
ciﬁcally targets activated factor X (FXa) of the blood
coagulation cascade.
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As the last serine protease in the blood coagulation cas-
cade, thrombin is the key enzyme responsible for physio-
logical ﬁbrin clot formation and platelet activation.
Thrombin also plays a prominent role in the pathologic
generation of occlusive thrombi in arteries or veins, a
process that may lead to arterial or venous thrombotic
disease. Thus, attenuation of the activity of thrombin—
either via direct inhibition or via blockade of other prote-
ases that lie upstream in the coagulation cascade and are
intimately involved in thrombin generation (e.g. FXa)—
has been intensively investigated as a novel means to
prevent and treat thrombotic disease.
Three key observations supported our hypothesis that
inhibition of FXa may represent an acceptable approach for
effective and safe antithrombotic therapy. First, as the
process of blood coagulation involves sequential activation
and ampliﬁcation of coagulation proteins, generation of
one molecule of FXa can lead to the activation of hundreds
of thrombin molecules [3]. In principle, therefore, inhibi-
tion of FXa may represent a more efﬁcient way of reducing
ﬁbrin clot formation than direct inhibition of thrombin
activity. This principle is consistent with an in vitro
observation, suggesting that inhibition of FXa but not
thrombin may result in a more effective sustained reduction
of thrombus-associated procoagulant activity [4]. Second,
inhibition of FXa is not thought to affect existing levels of
thrombin. Further, reversible FXa inhibitors might not
completely suppress the production of thrombin. These
small amounts of thrombin might be sufﬁcient to activate
high afﬁnity platelet thrombin receptors to permit physio-
logical regulation of hemostasis. Indeed, experimental
evidence from animal studies suggests that the antithrom-
botic efﬁcacy of FXa inhibitors is accompanied by a lower
risk of bleeding when compared with thrombin inhibitors
[5–7] (for review, see Hauptmann and Stu ¨rzebecher [8] and
Leadley [9]). Finally, the strongest evidence for FXa as an
antithrombotic drug target is the clinical proof of concept
studies of the indirect FXa inhibitor fondaparinux [10].
Taken together, these observations suggest that inhibition
of FXa is a potentially attractive antithrombotic strategy.
We initiated a drug discovery program on small-mole-
cule direct FXa inhibitors, with the goal of identifying
novel oral anticoagulants not burdened by the well-known
limitations of vitamin K antagonists such as warfarin,
agents that remain the only oral anticoagulants approved
for long-term use until very recently [11]. (On October 19,
2010, FDA approved the oral direct thrombin inhibitor
dabigatran etexilate to prevent stroke and blood clots in
patients with non-valvular atrial ﬁbrillation [12].) These
new FXa inhibitors would have the following target proﬁle.
First, they would be direct, highly selective and reversible
inhibitors of FXa, with a rapid onset of action, and would
demonstrate a relatively wide therapeutic index and few
food and drug interactions (thereby avoiding the need for
frequent coagulation monitoring and dose adjustment).
Second, these FXa inhibitors would have predictable
pharmacokinetic and pharmacodynamic proﬁles that allow
ﬁxed oral dosing, accompanied by low peak-to-trough
plasma concentrations that provide high levels of efﬁcacy
and low rates of bleeding. Finally, as the FXa target resides
in the central or blood compartment, the pharmacokinetic
proﬁle of these agents would also feature a low volume of
distribution (to minimize off-target risks) and low systemic
clearance (to reduce the potential for drug-drug
interactions).
Based on many years of research and development, we
have identiﬁed the potent, highly selective and direct FXa
inhibitor, apixaban (BMS-562247) [13–15]. Apixaban is
one of the most promising speciﬁc, single-target oral
anticoagulants in late clinical development. In clinical tri-
als, apixaban has been shown to provide predictable and
consistent anticoagulation, accompanied by promising
efﬁcacy and safety proﬁles in the prevention and treatment
of various thromboembolic diseases [16–22]. The phar-
macological and clinical proﬁles of apixaban suggest that it
has the potential to address many of the limitations of
warfarin therapy, currently the standard of care in chronic
oral anticoagulation. In this review, we summarize the
chemistry and pre-clinical proﬁle of apixaban.
Chemistry
Apixaban is a small-molecule, selective FXa inhibitor. It is
chemically described as 1-(4-methoxyphenyl)-7-oxo-6-[4-
(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyraz-
olo[3,4-c]pyridine-3-carboxamide. The molecular formula
for apixaban is C25H25N5O4, which corresponds to a
molecular weight of 459.5.
Discovery of apixaban
In the early 1990s, DuPont scientists invested a great
amount of effort in the development of inhibitors of gly-
coprotein IIb/IIIa. These efforts resulted in several com-
pounds that were advanced to clinical trials as potential
anti-platelet agents. By the mid-1990s, scientists at DuPont
had recognized similarities between the platelet glycopro-
tein GPIIb/IIIa peptide sequence Arg-Gly-Asp (RGD) and
the prothrombin substrate FXa sequence, Glu-Gly-Arg
(EGR). Consequently, a high-throughput lead evaluation
program was initiated to screen the IIb/IIIa library for FXa
inhibitory activity. This effort resulted in the identiﬁcation
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123of a small number of isoxazoline derivatives such as 1
(FXa Ki = 38.5 lM) (Fig. 1)[ 23]. Using molecular mod-
eling and structure-based design, an optimization strategy
resulted in the identiﬁcation of a benzamidine containing
FXa inhibitor 2 (SF303) with enhanced potency (FXa
Ki = 6.3 nM) and potent antithrombotic activity in an
experimental model of thrombosis [24–26]. Aside from the
key amidine P1 and the enzyme Asp189 interaction, the
biarylsulfonamide P4 moiety was designed to neatly stack
in the S4 hydrophobic box of FXa, which contains the
residues Tyr99, Phe174 and Trp215, with the terminal
O-phenylsulfonamide ring making an edge-to-face inter-
action with Trp215. Subsequent re-optimizations led to
vicinally substituted isoxazole analogs such as compound
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Fig. 1 The evolution of the
pyrazole-based FXa inhibitors:
the discovery of apixaban
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1233, which retained anti-FXa potency (FXa Ki = 0.1 nM)
[27] and a pyrazole analog 4 (SN429), which demonstrated
13 pM binding afﬁnity against FXa and good antithrom-
botic activity in a rabbit model of thrombosis [28, 29]. The
discovery of SN429 was tremendously important in that it
set the stage for an optimization strategy that led to the
discovery of several important compounds, such as 5
(DPC423), a phase I clinical candidate with a long terminal
half-life of approximately 30 h in humans [6, 28–30], and 6
(razaxaban) [31, 32], a compound that was advanced to a
phase II proof-of-principle clinical trial. In fact, razaxaban
was the ﬁrst small molecule FXa inhibitor to provide
clinical validation of the effectiveness of FXa inhibition
strategies [33].
Development of razaxaban was quickly followed by the
identiﬁcation of a novel bicyclic tetrahydropyrazolo-pyr-
idinone analog 7 (BMS-740808, FXa Ki = 0.03 nM) [34].
The evolution of the bicyclic pyrazole template allowed for
the incorporation of a diverse set of P1 groups, the most
important of which was the p-methoxyphenyl analog 8
(Ki = 0.14 nM) [13]. Compound 8 retained potent FXa
afﬁnity and good anticoagulant activity in vitro, was efﬁ-
cacious in in vivo rabbit antithrombotic models and
showed high oral bioavailability in dogs. A signiﬁcant
breakthrough was subsequently achieved, via the incorpo-
ration of a pendent P4 lactam group and a carboxamido
pyrazole moiety, that led to the discovery of 9 (BMS-
562247, FXa Ki = 0.08 nM) [13], a highly potent and
selective FXa inhibitor with good efﬁcacy in various ani-
mal models of thrombosis. Importantly, compound 9 also
showed an excellent pharmacokinetic proﬁle in dogs, with
low clearance, low volume of distribution and high oral
bioavailability [13]. The superior pre-clinical proﬁle dem-
onstrated by 9 enabled its rapid progression into clinical
development as apixaban [15]. Figure 2 illustrates the
X-ray structure of apixaban bound to FXa and shows the
p-methoxyphenyl P1 deeply inserted into the S1 pocket,
with the aryllactam P4 moiety neatly stacked in the
hydrophobic S4 pocket.
In vitro pharmacology
Potency, selectivity and kinetic mode of inhibition
Apixaban is a highly potent, reversible, active-site inhibitor
of human FXa, with a Ki of 0.08 nM at 25C and 0.25 nM
at 37C in the FXa tripeptide substrate (N-a-benzyloxy-
carbonyl-D-Arg-Gly-Arg-pNA) assay [35]. Analysis of
enzyme kinetics shows that apixaban acts as a competitive
inhibitor of FXa versus the synthetic tripeptide substrate,
indicating that it binds in the active site. Apixaban pro-
duces a rapid onset of inhibition under a variety of con-
ditions with association rate constant of 20 (lM
-1/s
approximately, and shows competitive inhibition of FXa
versus the synthetic tripeptide substrate. Reversibility
of FXa inhibition is demonstrated by the recovery of FXa
activity at 37C upon 200-fold dilution of a pre-formed
FXa:apixaban complex into tripeptide substrate, an effect
associated with a dissociation rate constant of
*0.0113 s
-1. Unlike indirect inhibitors of thrombin and
FXa, such as heparin, the low molecular weight heparins
and fondaparinux, apixaban, a direct FXa inhibitor, does
not require the presence of antithrombin III to inhibit FXa.
As shown in Table 1, apixaban has greater than 30,000-
fold selectivity for FXa relative to other human coagulation
proteases and structurally related enzymes involved in
digestion and ﬁbrinolysis [13].
In the prothrombinase assay, apixaban is an effective
inhibitor of the action of human FXa on its physiological
substrate, prothrombin, blocking the action of FXa on
prothrombin within the prothrombinase complex with a Ki
Fig. 2 X-ray structure of apixaban bound to factor Xa
Table 1 In vitro Ki values for inhibition of human enzymes by
apixaban at 25C[ 13]
Enzyme Ki (nM)
Factor Xa 0.08 ± 0.03
Activated protein C [30,000
Chymotrypsin 3,500
Factor IXa [15,000
Factor VIIa [15,000
Plasma kallikrein 3,700
Plasmin [25,000
Thrombin 3,100
Tissue plasminogen activator [40,000
Trypsin [20,000
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123of 0.62 nM [35]. It should be noted that when apixaban was
evaluated as an inhibitor of FXa versus the physiological
substrate prothrombin in its prothrombinase state, non-
competitive inhibition was observed. This ﬁnding is con-
sistent with prothrombin binding being dictated primarily
by interactions at exosites of FXa [36]. Apixaban also
inhibits thrombus-associated FXa activity with a concen-
tration causing 50% inhibition (IC50) of 1.3 nM [37]. In
summary, apixaban is capable of inhibiting the activity of
free FXa, thrombus-associated FXa and FXa within the
prothrombinase complex. Apixaban is a direct inhibitor of
FXa from rats, rabbits and dogs, with Ki values of 1.3, 0.16
and 1.7 nM, respectively (Table 2 [15]). Previous studies
involving other small molecule, direct FXa inhibitors have
also reported a species difference in FXa inhibition among
humans, rabbits, rats and dogs [29, 38, 39].
In vitro pharmacodynamic studies
To evaluate the in vitro pharmacodynamic activity of
apixaban in human plasma, studies were undertaken to
examine [1] thrombin generation, [2] anticoagulant activity
and [3] platelet aggregation. By inhibiting FXa, apixaban
prevents the conversion of prothrombin to thrombin,
resulting in decreased generation of thrombin. Using the
thrombogram method, apixaban was shown to inhibit tissue
factor-initiated thrombin generation in human platelet-poor
plasma in vitro. The IC50 of the rate of thrombin generation
was 50 nM, and the IC50 for attenuation of the peak
thrombin concentration was 100 nM [40]. In human
platelet-rich plasma, apixaban inhibited tissue factor-
induced thrombin generation, as measured by the release of
prothrombin fragment 1 ? 2, with an IC50 of 37 nM [41].
As expected for an inhibitor of FXa, addition of apix-
aban to normal human plasma prolonged clotting times,
including activated partial thromboplastin time (aPTT),
prothrombin time (PT), modiﬁed PT (mPT, using diluted
PT reagent) and HepTest. Among the three clotting time
assays, it appears that the mPT and HepTest are 10–20
times more sensitive than aPTT and PT in monitoring the
in vitro anticoagulant effect of apixaban in human plasma
(Table 2 [15]). In both the PT and aPTT assays, apixaban
had the highest potency in human and rabbit plasma, but
was less potent in rat and dog plasma, which parallels its
inhibitory potencies (Ki) against human, rabbit, rat and dog
FXa (Table 2 [15]).
In the human platelet aggregation assay, apixaban had
no direct effects on platelet aggregation response to ADP,
collagen, c-thrombin, a-thrombin and TRAP [15, 41].
However, it indirectly inhibited platelet aggregation
induced by thrombin derived from tissue factor-mediated
coagulation pathway, with an IC50 of 4 nM [41]. The potent
indirect antiplatelet effect of apixaban, together with its
direct antithrombotic and anticoagulant activity, suggests
that apixaban may possess dual mechanisms to prevent and
treat both venous (platelet-poor and ﬁbrin-rich) and arterial
(platelet-rich and ﬁbrin-poor) thrombosis. It should be
noted that the in vitro tissue factor model of platelet
aggregation is a useful tool for evaluation of the anti-
platelet mechanisms of action of anticoagulants. However,
caution should be exercised as in vitro antiplatelet poten-
cies of compounds obtained in this model may not directly
translate into antithrombotic potencies in patients in whom
multiple prothrombotic mechanisms, complications of
cardiovascular disease and polypharmacy are common.
In vivo pharmacology
The non-clinical pharmacology of apixaban has been
studied in vivo in rats and rabbits. Its in vivo effects were
assessed over a comprehensive dose range in various
well-established non-clinical models of thrombosis and
hemostasis. These non-clinical models have been well
characterized with standard antiplatelet agents and anti-
coagulants, making them appropriate for evaluating the
antithrombotic potential and bleeding liability of apixaban.
Antithrombotic and bleeding time effects in rats
Dose-dependent effects of apixaban were examined in a
broad range of experimental models of thrombosis and
hemostasis in rats [42]. Efﬁcacy was evaluated using
established models of thrombosis, including arterial-venous
Table 2 In vitro potency (Ki) of apixaban against human, rabbit, rat
and dog factor Xa (FXa) and the concentrations required to double
(EC29) the prothrombin time (PT), modiﬁed prothrombin time
(mPT), activated partial thromboplastin time (aPTT) and HepTest
in human, rabbit, rat or dog plasma [15]
Species FXa Ki (nM) PT EC29 (lM) mPT EC29 (lM) aPTT EC29 (lM) HepTest EC29 (lM)
Human 0.081 ± 0.002 3.6 0.37 7.4 0.4
Rabbit 0.16 ± 0.01 2.3 0.6 4.8 1.8
Rat 1.3 ± 0.1 7.9 n.d. 20 n.d.
Dog 1.7 ± 0.2 6.7 n.d. [20 n.d.
n.d. not determined
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123shunt thrombosis (AV-ST), tissue factor-stasis venous
thrombosis, and FeCl2-induced vena cava thrombosis and
carotid artery thrombosis. Hemostasis was assessed in
models of cuticle bleeding time, renal cortex bleeding time
and mesenteric bleeding time. Apixaban was given by a
continuous intravenous (IV) infusion 1 h prior to the
induction of thrombosis or bleeding.
Apixaban at 0.1, 0.3, 1 and 3 mg/kg/h IV produced
dose-dependent increases in ex vivo PT (1.24, 1.93, 2.75
and 3.98 times control, respectively). In the various models
of thrombosis, doses and plasma concentrations of apix-
aban for 50% thrombus reduction ranged from 0.39 to
1.55 mg/kg/h and 1.84 to 7.57 lM, respectively (Table 3)
[42]. The 3 mg/kg/h dose of apixaban increased cuticle,
renal and mesenteric bleeding times to 1.92, 2.13 and 2.98
times control, respectively. Bleeding time was not
increased by apixaban at 0.1 and 0.3 mg/kg/h in any model.
The 1 mg/kg/h dose produced an increase in mesenteric
bleeding time, but showed no effect on renal or cuticle
bleeding time. In comparison, heparin increased renal and
cuticle bleeding times to two times those of apixaban when
given at a dose (300 U/kg plus 10 U/kg/min IV) that
matched the efﬁcacy of apixaban (3 mg/kg/h IV) in arterial
thrombosis. These studies demonstrate that in rats, apix-
aban has broad-spectrum antithrombotic efﬁcacy and that
these beneﬁcial effects can be obtained at doses that show
limited activity in multiple models of provoked bleeding.
Antithrombotic and bleeding time effects in rabbits
The antithrombotic efﬁcacy of apixaban was evaluated in
anesthetized rabbits using established models of thrombo-
sis, including AV-ST, electrically induced carotid arterial
thrombosis (ECAT) and DVT (a thread-induced vena cava
thrombosis model). Hemostasis was assessed in a rabbit
model of cuticle bleeding time. Apixaban was given by a
continuous IV infusion 1 h prior to the induction of
thrombosis or cuticle incision.
Antithrombotic studies
Apixaban exhibited strong antithrombotic activity in the
rabbit models of AV-ST, ECAT and DVT, which com-
pared well with standard antithrombotic agents (Figs. 3, 4)
[7, 15, 43]. For instance, apixaban, the direct FXa inhibitor
rivaroxaban, the direct thrombin inhibitor dabigatran and
the oral anticoagulant warfarin showed similar efﬁcacy in
the prevention model of DVT (Fig. 3)[ 7, 15]. In the pre-
vention model of ECAT, apixaban was as efﬁcacious as the
antiplatelet agent clopidogrel and warfarin (Fig. 4)[ 7, 15,
43]. Doses and plasma concentrations of apixaban for 50%
thrombus reduction ranged from 0.07 to 0.27 mg/kg/h and
0.065 to 0.36 lM, respectively (Table 3)[ 15]. The 1 mg/
kg/h dose was associated with approximately 80% anti-
thrombotic efﬁcacy in these models. Interestingly, the
potency of apixaban in arterial and venous thrombosis
prevention models was broadly equivalent. Apixaban also
effectively inhibited the growth of a pre-formed intravas-
cular thrombus in a treatment model of DVT, suggesting
that apixaban shows potential for the treatment of estab-
lished thrombosis [7].
Bleeding time studies
The bleeding potential of apixaban was compared with
those of rivaroxaban, dabigatran and warfarin in the rabbit
cuticle bleeding time model [7, 15]. At the highest effec-
tive doses studied (each of which caused *80% inhibition
of thrombus formation), warfarin increased bleeding time
almost six-fold, whereas apixaban, rivaroxaban and da-
bigatran prolonged bleeding time 1.13-, 1.9 and 4.4-fold,
respectively (Fig. 3)[ 7, 15]. As shown in Fig. 3, the anti-
thrombotic efﬁcacy and bleeding proﬁles of warfarin and
dabigatran were less favorable than those of apixaban and
rivaroxaban. It should be noted; however, that extrapola-
tion of pre-clinical bleeding time data to humans requires
caution. Provoked bleeding measured in anaesthetized
healthy animals may not directly translate into spontaneous
bleeding observed in the clinical setting, where complica-
tions of cardiovascular disease and polypharmacy are often
present. Nevertheless, pre-clinical bleeding time studies are
still useful for generating hypotheses for clinical investi-
gation, for example by allowing the anti-haemostatic pro-
ﬁles of experimental agents to be ranked and compared
with those of established agents such as warfarin. The pre-
clinical comparison of these agents’ therapeutic windows,
Table 3 Potency of apixaban in multiple thrombosis models
Species Model
a ID50 (mg/kg/h)
b IC50 (lM)
b
Rat
c AV-ST 1.20 5.71
TF-VT 1.55 7.57
FeCl2-VT 0.39 1.84
FeCl2-AT 0.72 3.23
Rabbit
d AV-ST 0.27 0.36
pDVT 0.11 0.065
ECAT 0.07 0.11
a Experimental models included arterial-venous shunt thrombosis
(AV-ST), tissue factor-stasis venous thrombosis (TF-VT), FeCl2-
induced vena cava thrombosis (FeCl2-VT), carotid artery thrombosis
(FeCl2-AT), prevention model of deep vein thrombosis (pDVT) and
electrically induced carotid arterial thrombosis (ECAT)
b Potency for 50% decrease in thrombus weight was determined for
concentration (IC50) and dose (ID50)
c Data from Schumacher et al. [42]
d Data from Wong et al. [7, 15]
Preclinical discovery of apixaban 483
123as summarized in Fig. 3, remains a hypothesis, and head-
to-head clinical studies are required to validate these
results.
Combination therapy
Dual antiplatelet therapy with clopidogrel and aspirin
currently represents the standard of care for the reduction
of atherothrombotic events in a broad range of patients. To
understand the beneﬁt-risk ratio of apixaban therapy in
combination with standard antiplatelet therapy, apixaban
was evaluated in combination with clinically relevant doses
of aspirin and/or clopidogrel for the prevention of arterial
thrombosis in rabbit models [44]. These evaluations
showed that the triple combination of apixaban, aspirin and
clopidogrel resulted in improved antithrombotic activity
versus mono-therapies, without excessively increasing
bleeding time in rabbits. Such data suggest that intensive
antithrombotic therapy with apixaban, aspirin and clopi-
dogrel may be a viable option for enhancing antithrombotic
efﬁcacy without unacceptable increases in bleeding.
This hypothesis was tested in a large phase III study,
APPRAISE-2, in high-risk patients with recent ACS trea-
ted with apixaban or placebo in addition to mono (aspirin)
or dual antiplatelet (aspirin plus clopidogrel) therapy. Very
recently, the trial was discontinued based on ‘‘evidence of a
clinically important increase in bleeding among patients
randomized to apixaban, and this increase in bleeding was
not offset by clinically meaningful reductions in ischemic
events’’ [45]. The investigators of the APPRAISE-2 trial
will continue to review the available data to better under-
stand the effects of apixaban in this ACS patient population
and will publish the results [45].
As discussed above, the translatability of preclinical
bleeding models to safety in clinical settings requires
caution. It appears that the preclinical cuticle bleeding
Fig. 3 Plots of thrombus reduction and bleeding time versus dose in
apixaban, rivaroxaban, dabigatran and warfarin-treated rabbits.
Thrombus reduction, measured in the prevention model of venous
thrombosis, was expressed as the percentage reduction in thrombus
weight after treatment, relative to the mean vehicle thrombus weight.
Bleeding time effect was expressed as a ratio of treated versus the
mean vehicle value. Data are mean ± SE (n = 6 per group for the
thrombosis and bleeding time studies and n = 12 per dose for plasma
concentrations) (data from Wong et al. [7, 15]; reproduced with
permission). Reproduced from ‘‘Favorable therapeutic index of the
direct factor Xa inhibitors, apixaban and rivaroxaban, compared with
the thrombin inhibitor dabigatran in rabbits’’ published in ‘‘Journal of
Thrombosis and Haemostasis’’ (2009), John Wiley and Sons; and
from ‘‘Apixaban, an oral, direct and highly selective factor Xa
inhibitor: in vitro, antithrombotic and antihemostatic studies’’
published in ‘‘Journal of Thrombosis and Haemostasis’’ (2008), John
Wiley and Sons
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123effect of apixaban in combination with dual antiplatelet
therapy in rabbits does not translate directly into sponta-
neous bleeding observed in the APPRAISE-2 trial. The
underlying causes for this disconnect are not known, but
may be related to species differences, bleeding time versus
spontaneous bleeding, vascular bed differences, and the
fact that unlike animal bleeding models, the APPRAISE-2
patients had the highest tendency to bleed due to advanced
age, diabetes, complications of cardiovascular disease,
other comorbidities and the additive hazards of combina-
tion antiplatelet treatment. Finally, the APPRAISE-2 ﬁnd-
ing does not mean that apixaban cannot beneﬁt other
patient populations, as recent phase III clinical trials of
apixaban have demonstrated promising results in patients
with venous thromboembolism (ADVANCE 1, 2, 3) and
atrial ﬁbrillation (AVERROES) [18, 21, 22, 46].
Ex vivo coagulation markers
The traditional clotting time tests for adjusting anticoagu-
lant doses of heparin (aPTT) and warfarin (PT) are not
sensitive for speciﬁc, single-target anticoagulants such as
the FXa inhibitors. As shown in Fig. 5, apixaban only
prolonged ex vivo aPTT and PT modestly, even at the
highest dose that produced 80% antithrombotic efﬁcacy in
rabbits [7]. As expected from its mechanism of action,
apixaban did not prolong thrombin time (TT). Among the
clotting time tests, mPT was the most sensitive for apix-
aban and tracked well with the antithrombotic activity of
apixaban. Similar mPT results were also observed with
Fig. 4 Dose-dependent effects of apixaban, clopidogrel and warfarin
on integrated blood ﬂow in the electrically induced carotid arterial
thrombosis rabbit model. Data are mean ± SE (n = 6 per group,
except n = 12 for clopidogrel). *P\0.05 versus the corresponding
vehicle (V) (data from Wong et al. [15, 43]). Reproduced from
‘‘Apixaban, an oral, direct and highly selective factor Xa inhibitor: in
vitro, antithrombotic and antihemostatic studies’’ published in ‘‘Jour-
nal of Thrombosis and Haemostasis’’ (2008), John Wiley and Sons.
Fig. 5 Plots of thrombus reduction (bar graph) and ex vivo clotting
times (line graph) in apixaban-treated rabbits. Thrombus reduction,
measured in the prevention model of venous thrombosis, was
expressed as the percentage reduction in thrombus weight after
treatment, relative to the mean vehicle thrombus weight (data from
Fig. 3). For clarity, only mean data for thrombus reduction and the
bolus dose (mg/kg) are shown. Activated partial thromboplastin time
(aPTT), prothrombin time (PT), modiﬁed prothrombin time (mPT)
and thrombin time (TT) were expressed as the treated/control ratio.
Data are mean ± SE (n = 6 per group for thrombus reduction and
n = 12 per group for clotting times) (data from Wong et al. [7];
reproduced with permission). Reproduced from ‘‘Favorable thera-
peutic index of the direct factor Xa inhibitors, apixaban and
rivaroxaban, compared with the thrombin inhibitor dabigatran in
rabbits’’ published in ‘‘Journal of Thrombosis and Haemostasis’’
(2009), John Wiley and Sons
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123other FXa inhibitors such as rivaroxaban [7]. Data from a
phase II study with apixaban show that the anti-FXa assay
is more accurate and precise than the mPT test [47].
Indeed, we also observed that the anti-FXa assay tracked
well with antithrombotic activity in rabbits with arterial
thrombosis [15]. As shown in Fig. 6, apixaban produced a
dose-dependent inhibition of FXa and did not inhibit
thrombin activity ex vivo [15]. The ex vivo anti-FXa
activity of apixaban correlated well with both its anti-
thrombotic activity and plasma concentration (Fig. 6).
Thus, the anti-FXa activity assay may be suitable for
monitoring the anticoagulant and plasma levels of apixaban
if needed in certain situations such as an overdose, acute
bleeding or urgent surgery.
Drug metabolism and pharmacokinetics
The metabolism and pharmacokinetics of apixaban have
been studied extensively in animals and humans. In these
studies, absorption of apixaban after oral administration
was rapid, with a time to peak plasma concentration (Tmax)
of 1–2 h. Absolute oral bioavailability of apixaban was
good in rats, dogs and humans [48–50]. Following IV
administration, apixaban was slowly eliminated in rats,
dogs and humans, with an apparent terminal elimination
half-life (T1/2) of 2–11 h, and a total plasma clearance of
less than 5% hepatic blood ﬂow. The steady-state volume
of distribution for apixaban was low in rats, dogs and
humans (approximately 0.31 l/kg) [48–50]. Such steady-
state volume of distribution values are indicative of a large
portion of the drug remaining in the target compartment
(the blood). Apixaban had a higher clearance and a lower
bioavailability in rabbits compared with rats, dogs, chim-
panzees or humans [48–51]. In humans, apixaban has a low
peak-to-trough ratio of approximately 4 or less following
oral administration [52, 53]. Serum protein binding did not
appear to be concentration dependent in the range of 0.5–5
(lg/ml; protein binding was 92–96% in rats and dogs,
respectively, while binding was lower in humans, monkey
and rabbit plasma (87, 59 and 63%, respectively) [48].
Table 4 summarizes the pharmacokinetic properties of
apixaban in animal species and humans [19, 48–52].
In animals and humans receiving [
14C]apixaban, the
parent compound was the predominant component in
plasma and excreta (urine, bile and feces), although
numerous metabolites were detected at relatively low
concentrations [51, 53–55]. Metabolic pathways of apix-
aban in animals and humans are presented in Figs. 7 and 8.
In humans, O-demethyl apixaban (M2), O-demethyl
Fig. 6 Ex vivo anti-FXa and
anti-thrombin effects of
apixaban in arterial thrombosis
rabbits from Fig. 4 (top) and
correlation of ex vivo anti-FXa
with antithrombotic effects and
plasma concentrations of
apixaban in arterial thrombosis
rabbits (bottom). *P\0.05,
compared with the vehicle.
Mean ± SE and n = 6 per
group (data from Wong et al.
[15]; reproduced with
permission). Reproduced from
‘‘Apixaban, an oral, direct and
highly selective factor Xa
inhibitor: in vitro,
antithrombotic and
antihemostatic studies’’
published in ‘‘Journal of
Thrombosis and Haemostasis’’
(2008), John Wiley and Sons
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123apixaban sulfate (M1), 3-hydroxy apixaban (M7) and
hydroxylated O-demethyl apixaban (M13) were the most
abundant in vivo metabolites. Of these, O-demethyl apix-
aban sulfate was the predominant circulating human
metabolite, with levels of exposure to this metabolite
equivalent to approximately 25% of those of apixaban;
exposure to other metabolites did not exceed 5% of parent
[53]. Overall, approximately 25% of the dose was recovered
as metabolites in humans, primarily in the feces. O-Dem-
ethyl apixaban followed by O-demethyl apixaban sulfate,
3-hydroxy apixaban and hydroxylated O-demethyl apix-
aban, were the mostabundant metabolites inhuman excreta.
These metabolites were also formed in animal species
during non-clinical safety assessments. After administration
of [
14C]apixaban in mice, rats and dogs, no metabolite
exceeded 5% of the total plasma radioactivity at any time
point (measured up to 48 h after dosing). While O-demethyl
apixaban sulfate is the major human circulating metabolite,
it does not have meaningful pharmacological activity. In the
in vitro enzyme assay, this metabolite did not signiﬁcantly
inhibit puriﬁed human FXa at concentrations below 20 lM,
and did not inhibit thrombin or trypsin at concentrations up
to 30 lM. Furthermore, O-demethyl apixaban sulfate does
not possess structural alerts and is of no toxicological
concern [54].
Primary biotransformation reactions of apixaban include
O-demethylation and mono-oxidation; in some species,
opening of the keto-lactam ring and hydrolysis of the amide
moiety are additional minor pathways [55]. Combinations
of these reactions were also observed as sulfation of
O-demethyl apixaban, sulfation of hydroxylated O-dem-
ethyl apixaban and glucuronidation of O-demethyl apix-
aban (Figs. 7, 8). Apixaban was metabolized very slowly in
liver microsomes and hepatocytes, although O-demethyl
apixaban was formed in hepatocytes from all species, while
O-demethyl apixaban sulfate was detected in rat, monkey
and human hepatocytes only. No metabolites were formed
by human kidney microsomes or human intestinal S9
fraction. Similarly, no glutathione adduct of apixaban was
detected in microsomes or hepatocytes, indicating that the
Table 4 Comparison of pharmacokinetic and dispositional properties of apixaban in animal species and humans [48–57]
Parameters Human Rabbit Rat Dog Chimpanzee
Dose route IV PO IV PO IV PO IV PO IV PO
Dose (mg or mg/kg) 2.5 2.5 2.5 10 0.5 2.0 0.2 0.5 0.2 0.5
Cmax (lg/ml) NA 0.04–0.05 10.7 0.014 NA 1.1 NA 1.1 NA 1.6
Tmax (h) NA 1–4 NA 1 NA 0.5 NA 1.0 NA 2.0
AUC0-24 (lg h/ml) 0.7–0.9 0.41–0.45 1.66 0.05 2.0 2.7 3.9 8.0 10.1 13.6
CLTp or CL/F (ml/min/kg) 0.83 1.2 42.5 NA 4.3 NA 0.87 NA 0.30 NA
Vd (l/kg) 0.31 0.30 0.88 NA 0.31 NA 0.30 NA 0.17 NA
T1/2 (h) 5–9 8–13 0.6 NA 1.9 3.2 5 5.8 6.8 4.9
MRT (h) NA – 0.36 11.3 1.2 3.2 5.8 8.0 9.6 8.3
Oral bioavailability F% NA 51 NA 3 NA 34 NA 88 NA 51
Protein binding (%) 86.8–93.2 61.5–66.2 95.2–96.4 91.0–93.7 94.3–95.1
Renal elimination (% of dose) 25–28 (22–24 as
parent)
25 for IV and 2 for PO
(10 and\0.5 parent)
13.4 (12.1 as parent) 8.8 (7.2 as parent) ND
% of dose excreted as parent *56 *22–40 87.4 65.8 ND
Metabolic pathways O-Demethylation and
hydroxylation
O-Demethylation and
hydroxylation
O-Demethylation and
hydroxylation
O-Demethylation and
hydroxylation
ND
Circulating inactive metabolite O-Demethyl apixaban
sulfate
O-Demethyl apixaban
glucuronide
Minor O-demethyl
apixaban sulfate
Minor O-demethyl
apixaban sulfate
ND
A value range was reported for some kinetic parameters. Protein binding was 57.6–63.5 and 33.5–56.5% in monkey and mouse serum at
apixaban concentrations of 0.46–4.59 lg/ml
Protein binding in human serum albumin and alpha-1 acid glycoprotein was 66 and 9%, respectively
Blood-to-plasma ratio was 1.03 and 0.9 in dog and human, respectively
Urinary/fecal elimination (%) following administration of [
14C]apixaban was 15.2/83.9 (0–48 h; mouse PO), 13.4/74.0 (0–168 h; rat PO), 20.7/
12.7 (0–24 h; rat IV), 1.76/54.3 (0–48 h; rabbit PO), 24.8/62.4 (0–48 h; rabbit IV), 8.8/73.7 (0–168 h; dog PO) and 24.5/56.0 (0–292 h; human
PO). Urinary/fecal/bile elimination was 10.5/69.8/2.6 (0–48 h; rat PO) and 28.8/46.7/2.44 (0–216 h, 3–8 h for bile collection; human PO)
All metabolites represented 1.51% (urine)/10.7% (feces) and 15.4% (urine)/50.4% (feces) of dose in urine and feces of mouse and rabbit
following PO and IV administration of [
14C]apixaban, respectively
Cmax maximum plasma concentration, Tmax time to Cmax, AUC0-24 area under the plasma concentration–time curve from time 0–24 h, CLTp total
plasma clearance, Vd volume of distribution, T1/2 terminal elimination half-life, MRT mean residence time, F% oral bioavailability, NA not
applicable, ND not determined
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123formation of reactive metabolites with apixaban is unlikely.
The in vitro metabolism of apixaban was primarily medi-
ated by CYP3A4/5, with relatively minor contributions
from CYP1A2 and CYP2J2 towards the formation of
O-demethyl apixaban. In addition, low levels of O-dem-
ethyl apixaban formation were catalyzed by CYP2C8,
CYP2C9 and CYP2C19 [54]. The sulfation of O-demethyl
apixaban to form O-demethyl apixaban sulfate, the most
abundant circulating metabolite in humans, was primarily
catalyzed by the sulfotransferase SULT1A1 [54].
In animals receiving [
14C]apixaban, 8.7% (dog) to 47%
(rat) of the recovered radioactivity appeared in the urine as
apixaban, indicating that renal clearance was a route of
apixaban elimination [55]. Biliary clearance was a minor
apixaban elimination pathway (\5% of dose in limited
collection of bile of rats or humans following oral doses).
In bile duct-cannulated rats, 12% of an IV dose was
recovered in bile as apixaban (which was also detected in
the bile of humans receiving apixaban). Apixaban (at
amounts equivalent to 22% of the provided dose) was
recovered in the feces after IV administration to bile duct-
cannulated rats, suggesting that intestinal secretion of
apixaban also occurred. Metabolic clearance was less
important than, or of similar magnitude, to non-metabolic
clearance (direct excretion/secretion) in rats, dogs and
humans. Most of the recovery of metabolites was from the
feces. In summary, the elimination of apixaban involves
multiple pathways, including hepatic metabolism, renal
excretion and intestinal/biliary secretion, each responsible
for elimination of approximately one-third of dose.
Apixaban is a substrate for CYP3A4/5, BCRP and P-gp
[56]. Co-administration of drugs that modulate CYP3A4/5,
P-gp or BCRP activities could therefore potentially affect
the disposition of apixaban. Given that apixaban has mul-
tiple routes of elimination and an oral bioavailability of
approximately 50% [49, 50], any such drug–drug interac-
tion effects are likely to be of relatively low magnitude.
This hypothesis is supported by the results of clinical
drug–drug interaction studies that show that increases in
apixaban exposure are approximately twofold after coad-
ministration with a strong inhibitor of both CYP3A4 and
P-gp (i.e. ketoconazole), while an approximately 50%
decrease in apixaban exposure is observed after coadmin-
istration of apixaban with a strong inducer of both CYP3A4
and P-gp (i.e. rifampin) [50, 57]. The potential of apixaban
to inhibit or induce CYP is minimal, suggesting that
apixaban is unlikely to affect the metabolism of
co-administered medications that are dependent on
CYP-mediated clearance.
In summary, orally administered apixaban is well absor-
bed and bioavailable in humans. The compound has a rela-
tively simple metabolite proﬁle in human plasma, with the
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123only major metabolite an inactive sulfate conjugate. Apix-
aban is not a signiﬁcant inhibitor of CYP enzymes or P-gp
andsoisunlikelytobeasigniﬁcantperpetratorofdrug–drug
interactions. Apixaban is a substrate for CYP enzymes,
BCRP and P-gp, and may show some interaction with drugs
thatmodulateCYPenzymesorthesetransporters.However,
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Table 5 Phase III studies of apixaban
Indication Clinical trial Apixaban Comparator
VTE prevention
Knee replacement ADVANCE 1
a 2.5 mg bid
f Enoxaparin 30 mg bid
Knee replacement ADVANCE 2
b 2.5 mg bid Enoxaparin 40 mg qd
g
Hip replacement ADVANCE 3
c 2.5 mg bid Enoxaparin 40 mg qd
Acute medial illness ADOPT 2.5 mg bid Enoxaparin 40 mg qd
Atrial ﬁbrillation AVERROES
d 5 mg bid Aspirin 81–324 mg qd
ARISTOTLE 5 mg bid Warfarin (INR 2.0–3.0)
Acute coronary syndrome APPRAISE 2
e 5 mg bid on top standard
antiplatelet therapy
Placebo on top of standard
antiplatelet therapy
VTE treatment
Acute VTE AMPLIFY 10 mg bid (7 days) followed
by 5 mg bid (6 months)
Enoxaparin followed by
warfarin (INR 2–3)
VTE (after 6–12 months initial treatment) AMPLIFY-EXT 2.5 mg bid; 5 mg bid Placebo
a Completed [21];
b completed [22];
c completed [46];
d completed [18];
e discontinued [45];
f bid, twice oral daily dosing;
g qd, once oral daily
dosing
VTE venous thromboembolism
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123such interactions are unlikely to be of high magnitude since
apixaban is eliminated through multiple pathways.
Summary
In summary, apixaban is a novel and potent antithrombotic
agent in pre-clinical models. The antithrombotic actions of
apixaban are likely related to inhibition of FXa, but not to
thrombin inhibition. The high oral bioavailability, low
volume of distribution, low plasma clearance and favorable
therapeutic index exhibited by apixaban led to its selection
for clinical development as an oral anticoagulant. Clinical
studies suggest that apixaban may provide consistent
anticoagulation and a potentially optimal risk:beneﬁt bal-
ance. Phase III studies in patients undergoing total knee
replacement have shown that apixaban effectively reduces
the risk of venous thromboembolism in this setting, and is
associated with lower rates of clinically relevant bleeding
than the current standard of care in orthopedic surgery (the
low molecular weight heparin enoxaparin) [21, 22]. Other
potential indications for apixaban in the prevention and
treatment of various life-threatening thromboembolic
events are also under investigation in large-scale phase III
studies (Table 5).
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